Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.
作者信息
Lemoine Sandrine, Mornet Clelia, Quintin-Roue Isabelle, Rousselet Marie-Christine, Cottin Laurane, Georgeais Aurélie, Dubouis Ludovic, Boyer Françoise, Orvain Corentin, Caillon Clara, Renard Maxime, Le Brun Valoris, Le Clech Lenaig, Ianotto Jean-Christophe, Génin Emmanuelle, Burroni Barbara, Ugo Valérie, Luque Paz Damien, Lippert Eric
机构信息
Laboratoire d'Hématologie, CHU Angers, Angers, France; Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, France; Fédération Hospitalo-Universitaire "Grand Ouest Against Leukemia" (FHU GOAL), France; France Intergroupe des Syndromes Myéloprolifératifs (FIM).
France Intergroupe des Syndromes Myéloprolifératifs (FIM); Laboratoire d'Hématologie, CHRU Brest, Brest.
出版信息
Haematologica. 2022 Nov 1;107(11):2725-2731. doi: 10.3324/haematol.2022.280917.
Abstract
摘要
相似文献
1
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.130例慢性三阴性血小板增多症患者的组织学和遗传学特征及随访
Haematologica. 2022 Nov 1;107(11):2725-2731. doi: 10.3324/haematol.2022.280917.
2
Clinical significance of platelet count in patients with renal cell carcinoma.肾细胞癌患者血小板计数的临床意义
Urol Int. 2007;79(2):111-6. doi: 10.1159/000106322.
3
A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.根治性膀胱切除术治疗后癌症特异性生存的新预后模型，包括预处理血小板增多症和标准病理危险因素。
BJU Int. 2012 Dec;110(11 Pt B):E533-40. doi: 10.1111/j.1464-410X.2012.11231.x. Epub 2012 May 11.
4
Reactive thrombocytosis in children.儿童反应性血小板增多症
Turk J Pediatr. 2013 Jul-Aug;55(4):411-6.
5
Prognostic significance of thrombocytosis in patients with primary lung cancer.原发性肺癌患者血小板增多症的预后意义
Eur Respir J. 1996 Sep;9(9):1826-30. doi: 10.1183/09031936.96.09091826.
6
Is there a role for pre-operative thrombocytosis in the management of colorectal cancer?术前血小板增多症在结直肠癌治疗中的作用如何？
Int J Surg. 2010;8(6):436-8. doi: 10.1016/j.ijsu.2010.05.005. Epub 2010 Jun 4.
7
Etiology and clinical relevance of elevated platelet count in ICU patients : A retrospective analysis.重症监护病房患者血小板计数升高的病因及临床相关性：一项回顾性分析。
Med Klin Intensivmed Notfmed. 2018 Mar;113(2):101-107. doi: 10.1007/s00063-017-0276-y. Epub 2017 Mar 31.
8
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies.妇科恶性肿瘤患者术前血小板计数升高与血小板增多症
Arch Gynecol Obstet. 2017 Jan;295(1):9-15. doi: 10.1007/s00404-016-4212-9. Epub 2016 Oct 6.
9
Effect of iron supplementation on platelet count in adult patients with iron deficiency anemia.铁补充剂对缺铁性贫血成年患者血小板计数的影响。
Platelets. 2022 Nov 17;33(8):1214-1219. doi: 10.1080/09537104.2022.2091772. Epub 2022 Sep 1.
10
[The prognostic value of thrombocytosis in patients with primary lung cancer].[血小板增多症在原发性肺癌患者中的预后价值]
Ugeskr Laeger. 1998 Jun 22;160(26):3917-20.
引用本文的文献
1
Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.下一代测序鉴定出具有不同临床血栓形成结局的三阴性原发性血小板增多症患者亚组。
Int J Lab Hematol. 2025 Oct;47(5):869-876. doi: 10.1111/ijlh.14476. Epub 2025 Apr 7.
2
Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience.深度靶向测序对红细胞增多症和血小板增多症诊断的真实世界影响：一个参考中心的经验
Cancers (Basel). 2024 Sep 14;16(18):3149. doi: 10.3390/cancers16183149.
3
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征：对诊断、预后及治疗进展的意义
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
4
Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?骨髓活检在 MPN 中的定量解读——在分子时代有何意义？
Br J Haematol. 2023 Nov;203(4):523-535. doi: 10.1111/bjh.19154. Epub 2023 Oct 19.
5
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.维奈托克作为高危复发 AML 患者移植后的维持治疗是安全耐受的。
Bone Marrow Transplant. 2023 Aug;58(8):849-854. doi: 10.1038/s41409-023-01987-5. Epub 2023 Apr 25.
6
Genetic basis and molecular profiling in myeloproliferative neoplasms.骨髓增殖性肿瘤的遗传基础和分子谱分析。
Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578.
本文引用的文献
1
Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.疑似三阴性原发性血小板增多症的靶向二代测序突变分析：一项真实世界队列研究。
J Clin Pathol. 2021 Dec;74(12):808-811. doi: 10.1136/jclinpath-2020-206570. Epub 2020 Nov 3.
2
Essential thrombocytosis attributed to JAK2-T875N germline mutation.由 JAK2-T875N 种系突变引起的原发性血小板增多症。
Int J Hematol. 2019 Nov;110(5):584-590. doi: 10.1007/s12185-019-02725-8. Epub 2019 Aug 19.
3
Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.靶向二代测序在三阴性骨髓增殖性肿瘤患者中的诊断及预后价值
Am J Hematol. 2019 Oct;94(10):E264-E267. doi: 10.1002/ajh.25580. Epub 2019 Aug 6.
4
Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.T875N 体细胞突变在 JAK2 活性、结构稳定性和 OCI-AML3 细胞转化中的作用。
Int J Biol Macromol. 2019 Sep 15;137:1030-1040. doi: 10.1016/j.ijbiomac.2019.07.065. Epub 2019 Jul 9.
5
Cooccurring V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.同时发生的V617F和R1063H突变增加骨髓增殖性肿瘤中的JAK2信号传导和中性粒细胞增多。
Blood. 2018 Dec 20;132(25):2695-2699. doi: 10.1182/blood-2018-04-843060. Epub 2018 Oct 30.
6
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分类与个体化预后
N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.
7
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.携带两种驱动基因突变的骨髓增殖性肿瘤（MPN）患者的临床和生物学特征：一项法国骨髓增殖性肿瘤多中心研究（FIM）
Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12.
8
Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing.通过血小板分析和靶向测序对三阴性原发性血小板增多症患者进行分子特征分析。
Blood Cancer J. 2016 Aug 26;6(8):e463. doi: 10.1038/bcj.2016.75.
9
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
10
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.三阴性原发性血小板增多症患者存在非典型的血小板生成素受体（MPL）突变。
Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8.
Zotero 插件